Cantor Fitzgerald Issues Positive Outlook for NBIX Earnings

Key Points

• Cantor Fitzgerald has increased its FY2026 earnings per share (EPS) forecast for Neurocrine Biosciences to $7.38, up from a previous estimate of $6.53, significantly above the current consensus estimate of $4.28.
• Neurocrine Biosciences reported a quarterly EPS of $1.06, surpassing expectations, along with a revenue increase of 16.5% year-over-year to $687.50 million.
• Several analysts have upgraded their price targets for Neurocrine stock, with UBS raising it to $174.00 and Goldman Sachs initiating coverage with a target of $182.00.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for shares of Neurocrine Biosciences in a research note issued on Thursday, July 31st. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings per share of $7.38 for the year, up from their prior forecast of $6.53. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.08. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The firm had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. During the same period last year, the firm posted $1.63 EPS. The firm's revenue for the quarter was up 16.5% on a year-over-year basis.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group lifted their price target on shares of Neurocrine Biosciences from $158.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. The Goldman Sachs Group initiated coverage on shares of Neurocrine Biosciences in a report on Thursday, July 10th. They set a "buy" rating and a $182.00 price target for the company. Evercore ISI lowered their price target on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. BMO Capital Markets lifted their price target on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a report on Tuesday, May 6th. Finally, Stifel Nicolaus lifted their price target on shares of Neurocrine Biosciences from $166.00 to $174.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $160.90.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX traded up $0.04 during mid-day trading on Monday, hitting $128.43. 823,220 shares of the company's stock traded hands, compared to its average volume of 1,294,112. The firm's 50 day simple moving average is $128.53 and its 200 day simple moving average is $120.68. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $154.87. The company has a market cap of $12.74 billion, a PE ratio of 38.00, a price-to-earnings-growth ratio of 0.92 and a beta of 0.25.

Insider Buying and Selling

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 9,613 shares of the business's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the completion of the sale, the director owned 514,596 shares in the company, valued at $61,947,066.48. The trade was a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jude Onyia sold 59,819 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the sale, the insider owned 18,289 shares of the company's stock, valued at approximately $2,385,982.94. The trade was a 76.58% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 90,251 shares of company stock worth $11,672,602. Insiders own 4.30% of the company's stock.

Institutional Trading of Neurocrine Biosciences

Several institutional investors have recently added to or reduced their stakes in NBIX. Geneos Wealth Management Inc. increased its stake in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. Huntington National Bank grew its position in shares of Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after acquiring an additional 97 shares during the last quarter. WPG Advisers LLC bought a new position in shares of Neurocrine Biosciences during the first quarter worth about $32,000. Smallwood Wealth Investment Management LLC bought a new position in shares of Neurocrine Biosciences during the first quarter worth about $34,000. Finally, GeoWealth Management LLC grew its position in shares of Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after acquiring an additional 102 shares during the last quarter. Institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.